B J P Hupkens1,2, S O Breukink1, C Olde Reuver Of Briel3,4, P J Tanis5, M E de Noo6, P van Duijvendijk7, H L van Westreenen8, J W T Dekker9, T Y T Chen10, T Juul10. 1. Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands. 2. GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands. 3. Dutch Institute for Clinical Auditing, Leiden, The Netherlands. 4. Medical Research Data Management, Deventer, The Netherlands. 5. Department of Surgery, Academic Medical Centre, Amsterdam, The Netherlands. 6. Department of Surgery, Deventer Hospital, Deventer, The Netherlands. 7. Department of Surgery, Gelre Hospital, Apeldoorn, The Netherlands. 8. Department of Surgery, Isala Clinics, Zwolle, The Netherlands. 9. Department of Surgery, Reinier de Graaf Hospital, Delft, The Netherlands. 10. Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.
Abstract
AIM: The aim of this study was to validate the Dutch translation of the low anterior resection syndrome (LARS) score in a population of Dutch rectal cancer patients. METHOD: Patients who underwent surgery for rectal cancer received the LARS score questionnaire, a single quality of life (QoL) category question and the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire. A subgroup of patients received the LARS score twice to assess the test-retest reliability. RESULTS: A total of 165 patients were included in the analysis, identified in six Dutch centres. The response rate was 62.0%. The percentage of patients who reported 'major LARS' was 59.4%. There was a high proportion of patients with a perfect or moderate fit between the QoL category question and the LARS score, showing a good convergent validity. The LARS score was able to discriminate between patients with or without neoadjuvant radiotherapy (P = 0.003), between total and partial mesorectal excision (P = 0.008) and between age groups (P = 0.039). There was a statistically significant association between a higher LARS score and an impaired function on the global QoL subscale and the physical, role, emotional and social functioning subscales of the EORTC QLQ-C30 questionnaire. The test-retest reliability of the LARS score was good, with an interclass correlation coefficient of 0.79. CONCLUSION: The good psychometric properties of the Dutch version of the LARS score are comparable overall to the earlier validations in other countries. Therefore, the Dutch translation can be considered to be a valid tool for assessing LARS in Dutch rectal cancer patients. Colorectal Disease
AIM: The aim of this study was to validate the Dutch translation of the low anterior resection syndrome (LARS) score in a population of Dutch rectal cancerpatients. METHOD:Patients who underwent surgery for rectal cancer received the LARS score questionnaire, a single quality of life (QoL) category question and the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire. A subgroup of patients received the LARS score twice to assess the test-retest reliability. RESULTS: A total of 165 patients were included in the analysis, identified in six Dutch centres. The response rate was 62.0%. The percentage of patients who reported 'major LARS' was 59.4%. There was a high proportion of patients with a perfect or moderate fit between the QoL category question and the LARS score, showing a good convergent validity. The LARS score was able to discriminate between patients with or without neoadjuvant radiotherapy (P = 0.003), between total and partial mesorectal excision (P = 0.008) and between age groups (P = 0.039). There was a statistically significant association between a higher LARS score and an impaired function on the global QoL subscale and the physical, role, emotional and social functioning subscales of the EORTC QLQ-C30 questionnaire. The test-retest reliability of the LARS score was good, with an interclass correlation coefficient of 0.79. CONCLUSION: The good psychometric properties of the Dutch version of the LARS score are comparable overall to the earlier validations in other countries. Therefore, the Dutch translation can be considered to be a valid tool for assessing LARS in Dutch rectal cancerpatients. Colorectal Disease
Authors: J F Huisman; H L van Westreenen; E J van der Wouden; H F A Vasen; E J R de Graaf; P G Doornebosch; T J Tang; I Schot; R M Brohet; W H de Vos Tot Nederveen Cappel; M Vermaas Journal: Tech Coloproctol Date: 2019-07-23 Impact factor: 3.781
Authors: Veronica De Simone; Francesco Litta; Roberto Persiani; Gianluca Rizzo; Luigi Sofo; Roberta Menghi; Francesco Santullo; Alberto Biondi; Claudio Coco; Franco Sacchetti; Fabio Longo; Miriam Attalla El Halabieh; Rossana Moroni; Carlo Ratto Journal: Front Surg Date: 2022-06-20
Authors: Anne Asnong; André D'Hoore; Marijke Van Kampen; Nele Devoogdt; An De Groef; Kim Sterckx; Hilde Lemkens; Albert Wolthuis; Yves Van Molhem; Bart Van Geluwe; Lynn Debrun; Inge Geraerts Journal: BMJ Open Date: 2021-01-22 Impact factor: 2.692
Authors: Stijn H J Ketelaers; Maarten van Heinsbergen; Ricardo G Orsini; F Jeroen Vogelaar; Joop L M Konsten; Grard A P Nieuwenhuijzen; Harm J T Rutten; Jacobus W A Burger; Johanne G Bloemen Journal: Front Oncol Date: 2022-02-09 Impact factor: 6.244
Authors: Anne Asnong; André D'Hoore; Albert Wolthuis; Yves Van Molhem; Bart Van Geluwe; Annouschka Laenen; Nele Devoogdt; An De Groef; Tessa De Vrieze; Charlotte Van Calster; Inge Geraerts Journal: BMC Public Health Date: 2021-12-13 Impact factor: 3.295
Authors: Anu Carpelan; Eeva Elamo; Jukka Karvonen; Pirita Varpe; Sami Elamo; Tero Vahlberg; Juha Grönroos; Heikki Huhtinen Journal: Scand J Surg Date: 2020-06-18 Impact factor: 2.360
Authors: Anne Asnong; André D'Hoore; Albert Wolthuis; Yves Van Molhem; Bart Van Geluwe; Nele Devoogdt; An De Groef; Tessa De Vrieze; Lore Dams; Inge Geraerts Journal: Colorectal Dis Date: 2022-01-28 Impact factor: 3.917